What is LL37 and how does this cathelicidin antimicrobial peptide function in innate immunity?

LL37 is the only human cathelicidin antimicrobial peptide (AMP), a 37-amino-acid cationic peptide (Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH) that serves as a critical first-line defense molecule in innate immunity. LL37 is cleaved from the inactive C-terminal precursor hCAP18 (human cationic antimicrobial protein, 18 kDa) by protease-3 in neutrophils and kallikreins in epithelial cells, producing the bioactive 37-AA peptide. Mechanistically: (1) Direct antimicrobial activity - LL37 is amphipathic α-helical peptide with cationic regions (6 lysine, 6 arginine residues, net charge +6) and hydrophobic regions (leucine-rich N-terminus, phenylalanine clusters). This enables membrane interactions: LL37 binds anionic bacterial membranes (lipopolysaccharide in Gram-negatives, lipoteichoic acid in Gram-positives) via electrostatic attraction, inserts into bilayer via hydrophobic residues forming pores or causing membrane disruption (carpet model), resulting in bacterial lysis. LL37 kills broad spectrum: Gram-positive bacteria (S. aureus, S. epidermidis), Gram-negative bacteria (E. coli, P. aeruginosa, A. baumannii), mycobacteria (M. tuberculosis), fungi (C. albicans), and enveloped viruses (influenza, HSV, HIV) through membrane disruption. (2) Immunomodulatory functions - Beyond direct killing, LL37 orchestrates immune responses: chemotactic activity recruiting neutrophils, monocytes, T-cells, and mast cells to infection sites (binds formyl peptide receptor-like 1, FPRL1/FPR2), modulates cytokine production (induces IL-8, MCP-1; suppresses pro-inflammatory cytokines like TNF-α preventing excessive inflammation), promotes angiogenesis (VEGF induction, endothelial cell migration) important for wound healing, and enhances phagocytosis. (3) Endotoxin neutralization - LL37 binds and neutralizes LPS (endotoxin from Gram-negative bacteria) preventing LPS-TLR4 interaction and reducing septic shock severity. Similarly binds lipoteichoic acid (LTA) from Gram-positives. (4) Wound healing - LL37 promotes keratinocyte migration and proliferation, enhances re-epithelialization, stimulates angiogenesis, and modulates inflammation creating favorable healing environment. (5) Biofilm disruption - LL37 penetrates and disrupts bacterial biofilms (P. aeruginosa, S. aureus) which are typically resistant to antibiotics and host defenses. (6) Cancer-related functions - LL37 shows context-dependent effects: can be cytotoxic to cancer cells (membrane disruption, apoptosis induction) but in some cancers promotes angiogenesis and metastasis; research investigates this dual role. Research applications include antimicrobial resistance research, innate immunity studies, infectious disease models, wound healing, sepsis pathophysiology, biofilm infections, and developing novel antimicrobial therapeutics.

How does LL37's amphipathic α-helical structure enable antimicrobial activity?

LL37's antimicrobial potency derives from its amphipathic α-helical structure optimized for membrane disruption: (1) Secondary structure - In aqueous solution, LL37 exists in random coil or partially structured state. Upon encountering bacterial membranes (particularly anionic lipid interfaces), LL37 adopts α-helical conformation stabilized by intramolecular hydrogen bonding. Circular dichroism (CD) spectroscopy shows dramatic helicity increase from ~10% in water to ~60-80% in membrane-mimetic environments (sodium dodecyl sulfate, phospholipid vesicles). (2) Amphipathic character - The α-helix displays amphipathic topology: one face is highly hydrophobic (Leu-1, Leu-2, Phe-5, Phe-6, Phe-17, Phe-27, Val-21, Val-32, Ile-13, Ile-20, Ile-24) forming hydrophobic ridge, while opposite face is cationic (Lys-8, Lys-10, Lys-12, Lys-15, Lys-18, Lys-25, Arg-7, Arg-19, Arg-23, Arg-29, Arg-34) creating positive charge cluster. Helical wheel projections clearly demonstrate this segregation essential for membrane interaction. (3) Membrane binding mechanism - The cationic face electrostatically binds anionic bacterial membrane components (phosphatidylglycerol, cardiolipin, LPS, LTA), while mammalian cell membranes (neutral phosphatidylcholine, phosphatidylethanolamine on outer leaflet, anionic phosphatidylserine sequestered on inner leaflet) show weaker LL37 binding explaining selectivity for bacterial over host cells. (4) Membrane disruption models - After binding, the hydrophobic face inserts into lipid bilayer. Proposed mechanisms include: barrel-stave pore formation (multiple LL37 helices oligomerize forming transmembrane pore lined by hydrophobic residues facing lipids and cationic residues facing pore lumen allowing ion/water flux), toroidal pore model (LL37 induces lipid curvature creating pores lined by both peptide and lipid headgroups), or carpet model (LL37 covers membrane surface at high concentration causing micellization and membrane dissolution). Different bacteria may succumb to different mechanisms. (5) Structure-activity relationships - Mutagenesis studies reveal: N-terminal Leu-Leu residues critical for antimicrobial activity (deletion or substitution dramatically reduces potency), central Lys/Arg cluster essential for membrane binding (neutralizing positive charges abolishes activity), Phe residues important for membrane insertion and helical stability, and C-terminal region modulates immunomodulatory functions. (6) Conformational flexibility - LL37's ability to adopt different structures (random coil in solution, α-helix at membranes, potentially other structures in specific contexts) enables multifunctional roles beyond simple membrane disruption including receptor binding (FPRL1, P2X7), DNA binding (LL37 can bind DNA affecting gene expression), and protein-protein interactions.

What research applications benefit from LL37's antimicrobial and immunomodulatory properties?

LL37 excels in diverse research investigating innate immunity, infection, and host defense: (1) Antimicrobial resistance research - LL37 provides template for developing novel antimicrobials to combat resistant bacteria (MRSA, VRE, carbapenem-resistant Enterobacteriaceae, multidrug-resistant P. aeruginosa). Unlike antibiotics targeting specific pathways (allowing resistance mutations), LL37's membrane-disruption mechanism makes resistance development difficult. Studies testing LL37 analogs or mimetics with enhanced potency, stability, or reduced toxicity. Research examining LL37 combinations with conventional antibiotics investigating synergistic killing (LL37 membrane disruption enhances antibiotic penetration). (2) Wound healing and tissue repair - LL37 promotes keratinocyte migration, proliferation, and re-epithelialization in wound models. Diabetic wound healing research (chronic non-healing wounds common in diabetes) investigates LL37 as therapeutic: diabetic wounds show reduced endogenous LL37 expression, and supplementation improves healing rates, reduces infection, and enhances angiogenesis. Burn wound models examine LL37's dual benefit: antimicrobial protection (preventing Pseudomonas, Staphylococcus wound infections) plus healing promotion. (3) Infectious disease models - Testing LL37's efficacy against specific pathogens: tuberculosis research (LL37 shows mycobactericidal activity, enhances macrophage M. tuberculosis killing via autophagy induction), P. aeruginosa lung infections (LL37 disrupts biofilms and kills planktonic bacteria, relevant for cystic fibrosis research), S. aureus skin infections, C. albicans fungal infections, and viral infections (influenza, HSV, HIV where LL37 disrupts viral envelopes preventing cell entry). (4) Sepsis and endotoxemia - LL37 neutralizes LPS preventing TLR4 activation and cytokine storm. Animal sepsis models (cecal ligation puncture, LPS injection) examine whether LL37 administration reduces mortality, organ failure, and pro-inflammatory cytokine levels (TNF-α, IL-6, IL-1β). Research investigating LL37 as adjunct sepsis therapy. (5) Biofilm research - Biofilms confer antibiotic resistance and chronic infection persistence. LL37 disrupts P. aeruginosa, S. aureus, and polymicrobial biofilms relevant for catheter-associated infections, prosthetic joint infections, and chronic wounds. Studies combine LL37 with antibiotics or other antimicrobial peptides investigating synergistic biofilm eradication. (6) Mucosal immunity - LL37 is highly expressed in skin, respiratory tract, gastrointestinal tract, and genitourinary epithelium providing first-line defense. Research in inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), or vaginal infections examines LL37's protective vs pathogenic roles (LL37 deficiency increases infection susceptibility, but excessive LL37 may drive inflammation). (7) Vaccine adjuvant potential - LL37's immunomodulatory properties (chemotaxis, DC activation, cytokine modulation) make it candidate vaccine adjuvant enhancing antigen presentation and adaptive immunity. (8) Cancer biology - Context-dependent effects: investigating LL37 cytotoxicity to cancer cells (potential anti-cancer agent) vs pro-tumorigenic effects (angiogenesis, metastasis promotion in some cancers) determining when LL37 is beneficial vs harmful. (9) Autoimmune diseases - LL37 complexed with self-DNA can activate plasmacytoid dendritic cells driving interferon production in psoriasis and lupus; research investigates LL37's role in autoimmune pathogenesis.

What purity and quality standards does your LL37 meet for antimicrobial research?

Our LL37 exceeds >98% purity verified by reverse-phase HPLC demonstrating retention time characteristic of the 37-amino-acid cathelicidin sequence. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~4493 Da) validating the complete Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser sequence, peptide sequencing via MS/MS fragmentation or Edman degradation verifying each amino acid (special attention to 6 Lys, 6 Arg, 4 Phe, 3 Leu residues critical for antimicrobial structure-activity), amino acid composition analysis quantifying each residue confirming sequence fidelity and net charge +6, functional bioassays measuring antimicrobial activity including bacterial killing assays using Gram-positive (S. aureus ATCC 25923, including MRSA strains) and Gram-negative (E. coli ATCC 25922, P. aeruginosa PAO1) bacteria cultured to log-phase and treated with dose-escalating LL37 for 1-3 hours measuring colony forming units (CFU) reduction demonstrating dose-dependent killing with minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) quantification (typical MIC ranges 0.5-8 μg/mL depending on strain), time-kill kinetics showing rapid bactericidal activity (<1 hour for most strains), Gram-positive vs Gram-negative spectrum validation, fungal activity assays using C. albicans demonstrating antifungal potency, membrane disruption assays using propidium iodide uptake, SYTOX Green staining, or lactate dehydrogenase release confirming LL37 causes membrane permeabilization, biofilm disruption assays showing LL37 reduces pre-formed P. aeruginosa or S. aureus biofilms measured by crystal violet staining or metabolic activity (XTT reduction), chemotactic activity assays demonstrating LL37 recruits neutrophils or monocytes using transwell migration assays with dose-response quantification, cytokine modulation assays treating PBMCs or macrophages with LL37 +/- LPS measuring IL-8 induction and TNF-α modulation via ELISA, endotoxin neutralization assays showing LL37 inhibits LPS-induced NF-κB activation or cytokine production, circular dichroism (CD) spectroscopy confirming α-helical structure formation in membrane-mimetic environments (SDS micelles, phospholipid vesicles) with quantification of helical content, endotoxin testing (<0.1 EU/mg via LAL assay - critical for LL37 since it's used in LPS-related research), and comprehensive Certificate of Analysis. Cationic peptide handling: LL37's positive charge can cause non-specific binding to negatively charged surfaces (glass, some plastics); we recommend using low-binding tubes and including carrier proteins (0.1% BSA) in working solutions for dilute concentrations to prevent surface adsorption losses.

How should LL37 be stored, reconstituted, and handled to maintain antimicrobial potency?

LL37 storage and handling protocols to preserve antimicrobial and immunomodulatory activity: (1) Lyophilized storage - Store at -20°C in original sealed vials for 24+ months stability. The lyophilized 37-AA cationic peptide remains stable when dry and frozen. Avoid temperature fluctuations; maintain consistent -20°C. (2) Reconstitution - LL37's cationic nature (+6 net charge) requires specific reconstitution considerations. Add sterile water or low-salt buffer slowly down vial wall, gently swirl until dissolved at concentration 0.5-5 mg/mL. For antimicrobial assays requiring physiological salt, reconstitute initially in water then dilute in saline or culture medium (high salt during initial reconstitution can reduce solubility). If poor solubility occurs, brief sonication (15-30 seconds) or gentle warming (37°C, 5-10 minutes) helps dissolution. For immunological assays, reconstitute in PBS (pH 7.2-7.4) or Tris-buffered saline. (3) pH considerations - LL37 stability and activity are pH-dependent. Optimal pH range 6.0-8.0. Acidic pH ( 9.0) may cause deamidation of Asn/Gln residues. Antimicrobial activity is enhanced at slightly acidic pH (wound fluid, inflammatory sites often pH 6.0-6.5) but reduced at very acidic pH where positive charge may be over-protonated. (4) Salt sensitivity - High ionic strength can shield electrostatic interactions reducing LL37's membrane-binding and antimicrobial potency. Antimicrobial assays typically use low-salt media (Mueller-Hinton broth, minimal salts) for maximum activity measurement. When testing LL37 in physiological salt concentrations, expect 2-10 fold higher MIC values vs low-salt conditions; this reflects in vivo challenges LL37 faces. (5) Carrier proteins for dilute solutions - At concentrations <10 μM (~45 μg/mL), LL37 can adsorb to tube/plate surfaces causing concentration losses. Include 0.1% BSA or 0.1% gelatin as carrier protein preventing surface adsorption. Use low-binding tubes (siliconized or polypropylene) rather than standard polystyrene. (6) Reconstituted solution storage - Refrigerate at 2-8°C and use within 7-14 days for antimicrobial assays (peptide aggregation over time reduces activity). For longer storage, aliquot into single-use vials, flash-freeze, store at -20°C or -80°C, and thaw fresh aliquot before use. Minimize freeze-thaw cycles (maximum 2-3) as they promote aggregation. (7) Aggregation prevention - Cationic amphipathic peptides like LL37 can aggregate at high concentration or prolonged storage. If visible aggregates/precipitation occur, brief centrifugation (10,000g, 1 min) pellets aggregates allowing use of supernatant, though activity may be reduced. Fresh preparation from lyophilized powder is preferred over using old reconstituted stocks. (8) Sterility - Use aseptic technique for reconstitution, especially for cell-based assays or in vivo research. For bacterial killing assays, ensure sterility of LL37 stock via 0.22 μm filtration to prevent contamination confounding antimicrobial activity measurements.

How does LL37 selectivity for bacterial vs mammalian membranes work and what are the limitations?

LL37 shows preferential toxicity to bacteria over mammalian cells, but selectivity is not absolute, creating important research considerations: (1) Membrane composition differences - Bacterial membranes (particularly outer leaflet of cytoplasmic membrane and outer membrane of Gram-negatives) are highly anionic containing phosphatidylglycerol (PG), cardiolipin (CL), and LPS creating net negative surface charge. Mammalian cell membranes (outer leaflet) are predominantly neutral phosphatidylcholine (PC) and sphingomyelin with anionic phosphatidylserine (PS) restricted to inner leaflet by flippases. LL37's cationic character (+6 charge) preferentially binds anionic bacterial membranes via electrostatic attraction. (2) Cholesterol effects - Mammalian membranes contain ~40% cholesterol which increases membrane rigidity, reduces fluidity, and inhibits LL37 insertion and pore formation. Bacterial membranes typically lack cholesterol (except mycoplasma), making them more susceptible to LL37 disruption. Studies show cholesterol inclusion in model membranes dramatically reduces LL37 activity. (3) Concentration-dependent toxicity - At low concentrations ( 50 μM) can lyse mammalian cells, particularly erythrocytes (which lack nucleus and have limited repair capacity) and neutrophils. Hemolysis assays define therapeutic window: HC50 (concentration causing 50% hemolysis) vs MBC (minimum bactericidal concentration). Selectivity index = HC50/MBC; higher values indicate better selectivity. LL37 typically shows HC50 >100 μM and MBC 0.5-8 μM giving selectivity index of 12-200. (4) Cell-type differences in susceptibility - Mammalian cells with disrupted membrane asymmetry (cancer cells often expose PS on outer leaflet, apoptotic cells, activated platelets) show increased LL37 susceptibility. This explains LL37's anticancer activity against some tumors but raises toxicity concerns. (5) Context-dependent toxicity - In vivo, LL37 concentrations at infection sites (neutrophil granules release, epithelial secretion) can reach 100+ μM locally, potentially causing collateral damage to host cells contributing to inflammation. Research investigating whether LL37-induced tissue damage is beneficial (clearing infected/damaged cells) or harmful (excessive inflammation). (6) Immunomodulation vs direct killing - At sub-lethal concentrations (0.1-5 μM), LL37's primary functions may be immunomodulatory (chemotaxis, cytokine modulation, LPS neutralization) rather than direct antimicrobial killing, representing a safety mechanism. (7) Research implications - Antimicrobial peptide research uses selectivity assays: parallel bacterial killing and mammalian cell viability/hemolysis assays defining therapeutic window. LL37 analogs/mimetics aim to enhance selectivity (increased bacterial killing, reduced mammalian toxicity) through sequence modifications. Structure-activity studies identify residues determining selectivity (certain Lys→Arg substitutions, hydrophobic residue modifications, or cyclization/stapling strategies). (8) Limitations for therapeutic development - LL37's partial selectivity, susceptibility to proteolysis, high cost of synthesis (37 amino acids), and salt sensitivity limit clinical applications. Research focuses on truncated analogs (LL-17 to LL-37 fragments testing shorter active sequences), D-amino acid substitutions (protease resistance), or small molecule mimetics capturing antimicrobial activity without full peptide.

Can LL37 be combined with conventional antibiotics or other antimicrobial peptides?

Yes! LL37 combinations enable synergistic antimicrobial effects and overcome resistance: (1) LL37 + Conventional Antibiotics - Multiple studies demonstrate synergy between LL37 and antibiotics. Mechanisms: LL37 membrane disruption increases bacterial membrane permeability facilitating antibiotic entry (particularly beneficial for antibiotics targeting intracellular processes like ribosomes, DNA gyrase, RNA polymerase), LL37 neutralizes efflux pump activity (some bacteria use efflux pumps to expel antibiotics; LL37 membrane effects can disrupt pump function), LL37 potentiates antibiotic activity against biofilms (biofilm matrix blocks antibiotic penetration; LL37 disrupts matrix improving access). Specific combinations tested: LL37 + β-lactams (ampicillin, ceftazidime) show enhanced killing of resistant bacteria, LL37 + aminoglycosides (gentamicin, tobramycin) demonstrate synergy against P. aeruginosa biofilms, LL37 + fluoroquinolones (ciprofloxacin, levofloxacin) improve clearance in lung infection models, LL37 + vancomycin synergistic against MRSA. Checkerboard assays quantify synergy: fractional inhibitory concentration index (FICI) <0.5 indicates synergy; many LL37-antibiotic combinations achieve FICI 0.1-0.4. (2) LL37 + Other Antimicrobial Peptides - Combining different AMPs can provide complementary mechanisms: LL37 + Defensins (α-defensins like HNP1-3, β-defensins) - both are cationic AMPs but with different structures (LL37 α-helix vs defensins β-sheet with disulfides) and potentially different membrane interaction modes; combination shows additive or synergistic effects. LL37 + Magainins or other frog-derived AMPs - cross-species AMP combinations investigating synergy. LL37 + Lactoferricin - lactoferricin (from lactoferrin) has antimicrobial and immunomodulatory properties; combination enhances both activities. (3) LL37 + Antifungals - LL37 shows antifungal activity (C. albicans, Aspergillus); combination with azoles (fluconazole, voriconazole) or echinocandins (caspofungin) investigates synergistic fungal killing particularly against resistant strains or biofilms. (4) LL37 + Immunomodulators - LL37 + Cytokines (IFN-γ, G-CSF) examining synergistic immune activation and pathogen clearance. LL37 + Vitamin D - Vitamin D induces endogenous LL37 expression (via vitamin D response element in CAMP gene encoding hCAP18); exogenous LL37 + vitamin D supplementation may synergize particularly in vitamin D-deficient subjects with low baseline LL37. (5) LL37 + Antiseptics - LL37 + Silver nanoparticles or chlorhexidine for wound dressings or medical device coatings combining broad-spectrum antimicrobial coverage. (6) LL37 + Phage Therapy - Bacteriophages + LL37 provide dual mechanism: phages specifically infect/lyse bacteria while LL37 provides broad-spectrum coverage and immune modulation. (7) Resistance prevention - Combination therapy can reduce resistance development. Bacteria developing resistance to one agent remain susceptible to the other; LL37's membrane-disruption mechanism (difficult to develop resistance) complements antibiotic-specific targets. Research uses serial passage experiments: bacteria repeatedly exposed to sub-lethal LL37+antibiotic combinations show slower resistance development vs single agents. (8) Dose reduction benefits - Synergy allows lower doses of each component potentially reducing toxicity (lower LL37 concentration reduces mammalian cell toxicity, lower antibiotic dose reduces side effects) while maintaining efficacy.

How does proteolytic degradation affect LL37 and what strategies prevent it?

LL37 is susceptible to proteolytic degradation, a major challenge for therapeutic applications but also a regulatory mechanism in vivo: (1) Protease susceptibility - As a natural L-amino acid peptide, LL37 is substrate for various proteases: elastase (from neutrophils), cathepsins, matrix metalloproteinases (MMPs), and bacterial proteases (aureolysin from S. aureus, elastase from P. aeruginosa). Proteolysis occurs at multiple sites; elastase cleaves at Leu-Leu bonds (N-terminus), cathepsin D cleaves Phe-Phe bonds, generating truncated fragments with altered activity. Some fragments (LL-17 to LL-37, FK-13 to FK-37) retain antimicrobial activity; others lose function or gain different properties (some fragments more immunomodulatory, less bactericidal). (2) In vivo half-life - LL37 plasma half-life is short (~minutes to <1 hour) due to protease degradation and renal clearance (small peptide, <5 kDa). At infection/inflammation sites where LL37 is released, local protease concentrations (from neutrophil degranulation, tissue breakdown) can rapidly degrade LL37, but continuous local production (epithelial cells, neutrophils) maintains levels. (3) Disease-specific degradation - Some pathological conditions show altered LL37 degradation: cystic fibrosis airways have extremely high elastase activity rapidly degrading LL37 contributing to infection susceptibility, chronic wounds with high MMP activity degrade LL37 reducing antimicrobial defense, periodontitis with gingipain proteases (from P. gingivalis) degrade LL37. This creates therapeutic opportunity: exogenous LL37 supplementation or protease-resistant analogs. (4) Strategies for protease resistance - Research develops LL37 variants with enhanced stability: D-amino acid substitution - incorporating D-amino acids (mirror images of natural L-amino acids) at protease-sensitive sites blocks recognition by L-amino acid-specific proteases. All-D-LL37 shows complete protease resistance but may have altered bioactivity and immunogenicity. Partial D-substitution (strategic replacement at key cleavage sites) balances stability and activity. N-terminal or C-terminal modifications - acetylation, amidation, PEGylation, or other chemical modifications block exopeptidase degradation. N-terminal acetylation common in LL37 research. Cyclization or stapling - creating cyclic peptides or introducing chemical crosslinks (hydrocarbon staples between residues) increases conformational rigidity and protease resistance while potentially enhancing α-helical structure. Backbone modifications - peptoids (N-substituted glycines), β-peptides, or other non-natural backbones resistant to natural proteases. Encapsulation or delivery vehicles - liposomal LL37, nanoparticle formulations, or hydrogel matrices protect from proteases and enable sustained release. (5) Protease inhibitor co-administration - Combining LL37 with protease inhibitors (α1-antitrypsin, serine protease inhibitors) extends half-life, though inhibitors may have their own toxicity. (6) Research applications - Studies examining LL37 degradation kinetics in different biological fluids (serum, wound fluid, bronchoalveolar lavage, synovial fluid) using HPLC or mass spec tracking intact LL37 and degradation products over time. Testing protease-resistant LL37 analogs in protease-rich environments (CF sputum, chronic wound fluid) comparing activity to native LL37. Fragment activity assays identifying which proteolytic fragments retain antimicrobial or immunomodulatory functions - some truncated forms may represent natural fine-tuning of LL37 functions in vivo.

What documentation and international shipping support LL37 antimicrobial research?

We ship LL37 in lyophilized form with cold pack insulation in sealed packaging protecting the 37-amino-acid cationic antimicrobial peptide. Lyophilized LL37 remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the 37-AA cathelicidin sequence, mass spectrometry data confirming molecular weight (~4493 Da) validating the complete Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser sequence, peptide sequencing via MS/MS fragmentation verifying each amino acid with special validation of the 12 cationic residues (6 Lys, 6 Arg) critical for membrane binding and net charge +6, amino acid composition analysis quantifying each residue, functional bioassay data demonstrating antimicrobial activity including bacterial killing assays showing dose-dependent bactericidal activity against reference strains (S. aureus ATCC 25923, E. coli ATCC 25922, P. aeruginosa PAO1) with MIC and MBC quantification (typical range 0.5-8 μg/mL), time-kill kinetics demonstrating rapid bactericidal activity (<1 hour), MRSA activity confirming efficacy against resistant strains, membrane disruption assays via propidium iodide or SYTOX Green uptake confirming membrane permeabilization mechanism, biofilm disruption assays demonstrating LL37 reduces pre-formed biofilms, chemotactic activity assays showing dose-dependent neutrophil recruitment, cytokine modulation assays demonstrating LL37 induces IL-8 and modulates TNF-α in LPS-stimulated cells, circular dichroism spectroscopy confirming α-helical structure formation in membrane-mimetic environments (SDS micelles or phospholipid vesicles) with helical content quantification (~60-80% helicity), endotoxin testing (<0.1 EU/mg via LAL assay - critical since LL37 neutralizes LPS in functional assays), batch number and manufacturing date, handling recommendations for cationic peptides (use low-binding tubes, include carrier proteins for dilute solutions). This documentation satisfies institutional requirements worldwide ensuring compliance for antimicrobial resistance research, innate immunity studies, infectious disease models, wound healing research, biofilm investigations, and antimicrobial peptide development programs. For researchers requiring technical support on antimicrobial assays, membrane disruption measurements, or biofilm protocols, our team provides WhatsApp consultation on experimental design, optimal concentrations for different assays, and troubleshooting bacterial killing or immunological assays.

What dosage specifications and bulk pricing are available for LL37 antimicrobial research?

We offer three LL37 specifications to accommodate diverse antimicrobial research protocols: LL375 (5mg per 10-vial kit), LL3710 (10mg per 10-vial kit), and LL3740 (40mg per 10-vial kit - discontinued in favor of 10mg specification). Pricing with volume discounts: LL375: $170/kit (1 kit), $160/kit (20+ kits = 5.9% discount), $150/kit (50+ kits = 11.8% discount). LL3710: $340/kit (1 kit), $330/kit (20+ kits = 2.9% discount), $320/kit (50+ kits = 5.9% discount). The two concentration options support research from pilot antimicrobial screening and dose-response characterization (5mg for in vitro bacterial killing assays, MIC determinations, biofilm studies) to extensive in vivo infection models, chronic wound healing research, and large-scale antimicrobial resistance studies requiring higher cumulative doses (10mg supports multi-animal studies and prolonged treatment protocols). Pricing reflects synthesis complexity of the 37-amino-acid cationic peptide requiring solid-phase peptide synthesis (SPPS) assembling 37 residues with specific sequence including 12 cationic residues (6 Lys, 6 Arg requiring side-chain protection and careful deprotection to prevent modification), multiple hydrophobic residues (Leu, Phe, Val requiring aggregation management during synthesis and purification), potential for peptide aggregation during synthesis due to amphipathic character (careful solvent selection and temperature control essential), rigorous quality control (HPLC purity, mass spec confirming sequence and charge state, peptide sequencing validating all 37 residues, amino acid analysis confirming composition, comprehensive antimicrobial bioassays including bacterial killing against multiple strains with MIC/MBC quantification, membrane disruption assays, biofilm activity, chemotactic activity, cytokine modulation, circular dichroism confirming α-helical structure, endotoxin testing 98% purity. Bulk discounts support multi-year antimicrobial research programs, institutional infectious disease centers, pharmaceutical companies developing antimicrobial peptide therapeutics or analogs, wound healing product development, and international antimicrobial resistance research consortia. The longer 37-AA sequence makes LL37 more expensive than shorter peptides; pricing reflects synthesis yield challenges and purification costs. Contact via WhatsApp for custom quantities for clinical research or large animal studies requiring GMP-grade material for investigational therapies.

Home ProductsLL37

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

LL5

LL37

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade LL37 for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $245/kit

+$190

extra savings

Total Price

$340

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.18% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

LL37: Key Facts

LL37 is a immune support research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 1 format starting at $340 per kit. Each batch is independently HPLC-verified at 99.18% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	LL37
Research category	Immune Support
Available formats	5mg*10vials
Starting price	From $340 USD per kit
Purity	99.18% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Priya Desai

France

"Our microbiology research lab at a pharmaceutical research facility in Berlin has been using LyzeLabs LL37 for antimicrobial resistance research for 12 months with exceptional pharmaceutical quality. We independently verified >98.5% purity via HPLC and mass spectrometry confirmed the 37-amino-acid cathelicidin structure with molecular weight 4493 Da demonstrating complete sequence with all 12 cationic residues (6 Lys, 6 Arg). Our research investigates LL37 activity against multidrug-resistant bacteria - minimum inhibitory concentration (MIC) assays show LL37 potency against MRSA (MIC 2-4 μg/mL), carbapenem-resistant Klebsiella (MIC 4-8 μg/mL), and MDR P. aeruginosa (MIC 8-16 μg/mL) demonstrating activity retained against antibiotic-resistant strains. Time-kill kinetics reveal rapid bactericidal activity (>99.9% killing within 1 hour at 2× MIC). Biofilm disruption assays using crystal violet staining show LL37 (10-50 μg/mL) reduces pre-formed S. aureus biofilms by 65-82% (p<0.01) relevant for catheter infections. Membrane permeabilization assays via SYTOX Green uptake confirm LL37's membrane-disruption mechanism (dose-dependent fluorescence increase indicating bacterial membrane integrity loss). Synergy checkerboard assays combining LL37 + ciprofloxacin against P. aeruginosa demonstrate FICI 0.25 indicating strong synergy enabling 4-fold reduction in each agent's effective concentration. We're investigating LL37 in diabetic wound infection models - topical LL37 reduces bacterial burden and accelerates healing. Circular dichroism confirms α-helical structure in membrane environments. The LL3710 specification supports our multi-strain testing protocols. Delivery to Berlin takes 11-13 days with excellent cold-chain packaging. Premier antimicrobial peptide for international infectious disease research."

2025-11-15

Priya N.

United States

"Everything checked out on receipt. Labeling matched the certificate."

2025-11-12

Nathan P.

Sweden

"First order came through clean. Cross-referenced the COA, it held."

2025-11-09

About This Product

LL-37 Cathelicidin Research Guide

The Human Antimicrobial Peptide

LL-37 is the mature form of the only cathelicidin antimicrobial peptide found in humans, derived from the precursor protein hCAP-18. It is a 37 amino acid peptide that begins with two leucine residues (hence the name), and it is one of the most studied antimicrobial peptides in human biology. LL-37 is produced by neutrophils, epithelial cells, and keratinocytes as part of the innate immune response against bacterial, viral, and fungal pathogens.

Its research interest extends well beyond direct antimicrobial activity. LL-37 has documented effects on wound healing, angiogenesis, chemotaxis, and inflammatory modulation, which makes it a multifunctional research tool across innate immunity, tissue repair, and inflammatory biology.

Mechanism

Direct antimicrobial activity: LL-37 disrupts bacterial membranes through a charge-based mechanism, with activity against gram-positive, gram-negative, and some mycobacterial species
Chemotactic signaling: recruits neutrophils, monocytes, and T lymphocytes to sites of infection or injury
Pro-angiogenic effects: promotes endothelial cell proliferation and wound vascularization
Immune modulation: shifts cytokine production toward inflammation resolution in research models
Anti-biofilm activity: disrupts bacterial biofilm formation, a significant research topic in chronic infection models

Research Applications

Innate immunity research involving cathelicidin biology
Antimicrobial peptide pharmacology and bacterial membrane disruption research
Wound healing research combining antimicrobial and pro-healing effects
Biofilm disruption research
Inflammatory modulation research
Comparative research against synthetic antimicrobial peptides and small-molecule antibiotics

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For research purposes only. Not for human consumption or therapeutic use.

Research Context for LL37

Immune Modulation Research Context

Immune research peptides are studied for effects on T-cell maturation, innate immune response, cytokine signaling, and the thymic-derived immune modulation pathway. Protocols in this category often involve longitudinal immune biomarker tracking and specific infection or inflammation models.

LL37 ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Immune Support category, available as a single research-grade format. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Immune Support Category

Thymosin Alpha-1

Thymalin

Research Tools for This Compound

Frequently Asked Questions

LL37

$340